Inhibitions of chemokines and their corresponding receptors, such as inhibition of the CXCL1-CXCR2 axis and CCL2-CCR2 axis, have been suggested as a therapeutic approach in treating cardiovascular diseases such as HF, coronary artery diseases, and cardiac arrhythmia [[57], [58], [59], [60], [61]]. The gene discussed is CCL2; the disease is cardiovascular disorder.